JP2022547809A5 - - Google Patents

Info

Publication number
JP2022547809A5
JP2022547809A5 JP2022510984A JP2022510984A JP2022547809A5 JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5 JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5
Authority
JP
Japan
Prior art keywords
amino acid
cell
acid sequence
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022510984A
Other languages
English (en)
Japanese (ja)
Other versions
JP7737978B2 (ja
JP2022547809A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047071 external-priority patent/WO2021034976A1/en
Publication of JP2022547809A publication Critical patent/JP2022547809A/ja
Publication of JP2022547809A5 publication Critical patent/JP2022547809A5/ja
Application granted granted Critical
Publication of JP7737978B2 publication Critical patent/JP7737978B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022510984A 2019-08-20 2020-08-19 Wt-1に特異的なt細胞免疫療法 Active JP7737978B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889519P 2019-08-20 2019-08-20
US62/889,519 2019-08-20
PCT/US2020/047071 WO2021034976A1 (en) 2019-08-20 2020-08-19 T-cell immunotherapy specific for wt-1

Publications (3)

Publication Number Publication Date
JP2022547809A JP2022547809A (ja) 2022-11-16
JP2022547809A5 true JP2022547809A5 (enExample) 2023-08-29
JP7737978B2 JP7737978B2 (ja) 2025-09-11

Family

ID=72473955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510984A Active JP7737978B2 (ja) 2019-08-20 2020-08-19 Wt-1に特異的なt細胞免疫療法

Country Status (9)

Country Link
US (1) US12653886B2 (enExample)
EP (1) EP4017872A1 (enExample)
JP (1) JP7737978B2 (enExample)
KR (1) KR20220050176A (enExample)
CN (1) CN114555790B (enExample)
AU (1) AU2020334064A1 (enExample)
CA (1) CA3147717A1 (enExample)
IL (1) IL290609A (enExample)
WO (1) WO2021034976A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202406990D0 (en) * 2024-05-16 2024-07-03 Univ Oxford Innovation Ltd T cell receptors and uses thereof
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2026125718A1 (en) * 2024-12-13 2026-06-18 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
EP1550453B1 (en) 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
JP6476182B2 (ja) * 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトt細胞受容体
US11390921B2 (en) * 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
EP3177314B1 (en) * 2014-08-04 2020-10-07 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2017112944A1 (en) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
AU2017232431A1 (en) 2016-03-15 2018-09-20 Cancer Research Technology Limited Chimeric antigen receptor
KR102397771B1 (ko) 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
EA201992536A1 (ru) 2017-04-24 2020-03-05 Оспедале Сан Раффаэле С.Р.Л. Tcr и пептиды
PL3765615T3 (pl) 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna

Similar Documents

Publication Publication Date Title
US11932700B2 (en) Use of chimeric antigen receptor modified cells to treat cancer
JP2024074801A5 (enExample)
Kershaw et al. Gene-engineered T cells for cancer therapy
Fan et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Feldman et al. Adoptive cell therapy—tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors
JP2017523784A5 (enExample)
US20230265207A1 (en) T cell-antigen coupler with y182t mutation and methods of uses thereof
US10654934B2 (en) Use of chimeric antigen receptor modified cells to treat cancer
JP2020509767A5 (enExample)
JP2017531687A5 (enExample)
RU2017114174A (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
JP2021512637A5 (enExample)
JP2022525099A5 (enExample)
JP2022527267A5 (enExample)
BR112021000735A2 (pt) acoplador de antígeno de células t com várias otimizações de construto
JP2022523971A5 (enExample)
Pircher et al. T cell engineering
JP2022523553A5 (enExample)
JP2022543059A5 (enExample)
JP2021525067A5 (enExample)
WO2018064921A1 (en) Use of chimeric antigen receptor modified cells to treat cancer
JP2022543058A5 (enExample)
JP2022543060A5 (enExample)
Hanagiri et al. Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes
Smith et al. Immunotherapy of colorectal cancer